PRESENTATION

Q2 2025 — Presentation

Q2 2025PDF · 15 pages213 KB
Elevance Health
2Q 2025 Earnings Presentation
July 17, 2025

-- 1 of 15 --

22
The Value We Deliver
We advance whole health through innovative solutions that integrate physical,
behavioral, and social care to achieve our purpose of improving the health of humanity
For Consumers
Simple, Affordable, and Accessible Health Care
1. 	Simplifying healthcare through enhanced digital
capabilities that personalize member experiences
2. 	Affordability at the core of our innovative plan designs
3. 	Accessibility through advocacy and data driven solutions
that elevate whole health
1. 	Differentiated clinical partnerships built on shared
expertise and coordinated care
2. 	Advanced clinical collaboration and value-based care
3. 	Aligned business partner through digital tools
that enhance information exchange and reduce
administrative burden
For Care Providers
Deepen Clinical and Business Partnerships

-- 2 of 15 --

3
Key Highlights
• 	Elevance Health second quarter results reflect disciplined execution
• 	Operating revenue of $49.4B grew more than 14%
• 	Medical loss ratio of 88.9% increased 260 bps
• 	Adjusted diluted EPS1 of $8.84
• 	Returned $2.0B to shareholders year-to-date through dividends and share repurchases
2Q 2025 Results
1
• 	Revising full year adjusted diluted EPS1 guidance to approximately $30.00
• 	2025 benefit expense ratio to be approximately 90.0%, reflecting the ongoing and industry-wide impact of
elevated cost trends in our ACA and Medicaid businesses
• 	Updating operating cash flow guidance to approximately $6.0 billion, primarily reflecting our revised
earnings outlook and unfavorable working capital impacts
2025 Outlook
2
• 	Elevance Health is executing a clear strategy to strengthen performance and drive our enterprise flywheel
• 	Accelerating our capabilities through advanced digital and AI tools to personalize the healthcare journey
• 	Actively streamlining prior authorizations, with over half of electronic requests now processed in real time
• 	Investing in advanced analytics to identify and reduce wasteful spending and enhance system integrity
• 	Ensuring long-term, sustainable growth through disciplined pricing, growth in Carelon, and expansion of
value-based care models to deliver value for our members and shareholders over time
Strategic Focus Areas
3
1. 	See “GAAP Reconciliation” on slides 12 and 13 herein.

-- 3 of 15 --

44
Key Highlights
• 	Elevance Health second quarter results
reflect the diversity and resilience of
our business as we navigate an
elevated trend environment
• 	Operating revenue of $49.4B grew
14.3%, attributable to higher premium
yields in Health Benefits, recently closed
acquisitions, and increased Medicare
Advantage membership (partially
offset by Medicaid attrition)
• 	Medical loss ratio of 88.9% primarily
reflects slower Medicaid rate alignment
and higher ACA cost trends
• 	Adjusted operating expense ratio was
10.0%, an improvement of 140 bps,
reflecting expense leverage and our
ongoing commitment to disciplined
cost management
• 	Operating cash flow of $2.1B included
an improved working capital position
2Q 2025 Results
Change (%/bps)	2Q 2024	2Q 2025	Elevance Health
14.3%	$43.2B	$49.4B	Operating Revenue 1
260 bps	86.3%	88.9%	Medical Loss Ratio
(140) bps	11.4%	10.0%	Adjusted Operating Expense Ratio1,2
(14.2%)	$2.9B	$2.5B	Adjusted Operating Gain1,2
(170) bps	6.7%	5.0%	Adjusted Operating Margin 1,2
(4.3%)	$508M	$486M	Net Investment Income
(14.2%)	$10.30	$8.84	Adjusted Diluted EPS 2
$1.6B	$0.4B	$2.1B	Operating Cash Flow
1. 	See “Basis of Presentation” on slide 11 herein.
2. 	See “GAAP Reconciliation” on slides 12 and 13 herein.

-- 4 of 15 --

55
Key Highlights
• 	Health Benefits second quarter results
reflect accelerated revenue growth;
membership mix shifts and elevated
utilization weighed on operating gain
• 	Operating revenue grew 11.9% year
over year, driven by higher premium
yields, recently closed acquisitions, and
growth in Medicare Advantage
membership (partially offset by
Medicaid attrition)
• 	Adjusted operating margin of 3.8%
declined by 200 bps, due to higher
Medicaid and ACA cost trend, partly
offset by operating efficiencies
• 	Membership of 45.6M reflects Medicaid
redeterminations, offset by targeted
growth and higher retention rates in
Medicare Advantage, and increases in
Commercial risk-based membership
Change (%/bps)	2Q 2024	2Q 2025	Health Benefits
11.9%	$37.2B	$41.6B	Operating Revenue 1
(27.8%)	$2.2B	$1.6B	Adjusted Operating Gain1,2
(200) bps	5.8%	3.8%	Adjusted Operating Margin 1,2
(0.3%)	45.8M	45.6M	Membership
1. 	See “Basis of Presentation” on slide 11 herein.
2. 	See “Reportable Segment Highlight Details” on slide 14 herein.
Health Benefits
2Q 2025 Results

-- 5 of 15 --

66
Key Highlights
• 	Strong revenue growth fueled by the
scaling of innovative risk-based
capabilities and integration of
acquisitions, underscoring our
strategic focus on advancing our
enterprise flywheel for growth
• 	CarelonRx operating revenue includes
growth in adjusted scripts and
contribution from recent acquisitions in
specialty pharmacy services; adjusted
operating margin impacted by ongoing
initiatives to accelerate growth as we
expand up market
• 	Carelon Services operating revenue
expansion of over 60% reflects the
addition of CareBridge and the scaling
of risk-based solutions; adjusted
operating margin reflects improved
Carelon Health performance, slightly
offset by the dilutive effect of
CareBridge
2Q 2025 Results
Change (%/bps)	2Q 2024	2Q 2025	Carelon
35.8%	$13.3B	$18.1B	Operating Revenue 1
25.0%	$0.7B	$0.9B	Adjusted Operating Gain1,2
(40) bps	5.6%	5.2%	Adjusted Operating Margin 1,2
6.5%	78.2M	83.3M	Adjusted Scripts
(4.9%)	102.3M	97.3M	Consumers Served
1. 	See “Basis of Presentation” on slide 11 herein.
2. 	See “Reportable Segment Highlight Details” on slide 14 herein.
Health Services

-- 6 of 15 --

77
Flywheel Supports Our Long-Term Growth Algorithm
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Targeting at least 12% average annual growth in
Adjusted Diluted Earnings Per Share
Approximately 46M medical members
balanced across commercial,
Medicaid and Medicare, leveraging
the assets and capabilities of Carelon
to accelerate growth
As an integrated portfolio of whole
health solutions serving approximately
100M consumers, Carelon connects care
across physical, behavioral, social,
home health, and pharmacy needs to
bend the cost curve, enhance consumer
experiences, and deliver whole health,
affordably
Health Services

-- 7 of 15 --

88
Adjusted Operating Gain – High Single Digit to Low Double Digit CAGR1
Long-Term Growth Algorithm
Revenue Growth
High Single Digit CAGR1
Adjusted Operating Margin
Expanding to 6.5% - 7.0%
Capital Deployment
Approximately 4% Contribution to
Adjusted Diluted EPS CAGR 1
Health Benefits
Mid to High Single Digit CAGR
Driven by membership growth, cost trend, geographic
expansion, and growth in specialized populations
Carelon Services
High Teens to Low Twenties CAGR
Driven by risk-based revenue growth including M&A
CarelonRx
Low Double Digit CAGR
Driven by script volumes and drug mix
Transforming our business
processes by leveraging new
technologies across operations
Commitment to operating
efficiency and optimizing core
businesses
Effective medical management
Underwriting discipline
Share Repurchases
Organic Reinvestment
Programmatic M&A targeting
integrated solutions that
strengthen health plan
competitiveness
+ 	+
Targeting at least 12% average annual growth in Adjusted Diluted EPS
1. 	CAGR = Compound Annual Growth Rate Target.

-- 8 of 15 --

99
Committed to Strong Growth Over the Long-Term
M&A/ Organic
Reinvestment
50%
Share
Repurchase
30%
Dividends
20%
5.3%
6.5% – 7.0%
2024 	Target
$175B
High Single
Digit CAGR1
2024 	Target
Elevance Health
5.8%
Mid to High
Single Digit
2024 	Target
$54B
Mid Teens
CAGR1
2024 	Target
Carelon 2
4.2%
5.5% – 6.5%
2024 	Target
$150B
Mid to High
Single Digit
CAGR1
2024 	Target
Health Benefits
Capital
Allocation
Targeting at least 12% average annual
growth in Adjusted Diluted EPS
Adjusted 3
Operating
Margin
Revenue
(in billions)
1. 	CAGR = Compound Annual Growth Rate Target.
2. 	The CAGR target for revenue and the operating margin target for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin target for CarelonRx,
and (ii) a high teens to low twenties revenue CAGR and mid to high single digit operating margin for Carelon Services.
3. 	See “GAAP Reconciliation” on slides 12 and 13 herein.

-- 9 of 15 --

10
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views
about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,”
“project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and
estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements
regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could
cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our
reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the
extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties
include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large
scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws
or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application;
the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations,
claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial
intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that
may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic
growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed
thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to
revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits
or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and
services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS
Health, L.L.C.; the effects of any negative publicity related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and
strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in
the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our
common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness
and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings;
events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our
international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

-- 10 of 15 --

11
Non-GAAP Measures and Basis of Presentation
This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and
are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures
calculated in accordance with GAAP are available on Slides 12-13 of this document.
Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set
incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of
products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible
assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in
understanding and analyzing Elevance Health’s operating and financial results.

-- 11 of 15 --

12	12
Elevance Health GAAP Reconciliation — Shareholders’ Net Income
and Shareholders’ Earnings Per Diluted Share Six Months Ended Jun 30	Three Months Ended Jun 30
Change	2024	2025	Change	2024	2025	(In millions, except per share data)
(13.6)%	$4,546	$3,926	(24.2)%	$2,300	$1,743	Shareholders' net income
Add / (Subtract):
278	302	162	147	Amortization of other intangible assets
246	595	85	131	Net losses on financial instruments
116	133	64	53	Transaction and integration related costs1
11	15	9	10	Litigation and settlement expenses1
119	—	59	—	Business dispositions and related items 2
—	—	4	—	Business optimization charges 1
(240)	—	(240)	—	Gain on sale of business
(134)	(255)	(38)	(87)	Tax impact of non-GAAP adjustments
396	790	105	254	Net adjustment items
(4.6)%	$4,942	$4,716	(17.0)%	$2,405	$1,997	Adjusted shareholders' net income
(10.9)%	$19.44	$17.33	(21.6)%	$9.85	$7.72	Shareholders’ earnings per diluted share
Add / (Subtract):
1.19	1.33	0.69	0.65	Amortization of other intangible assets
1.05	2.63	0.36	0.58	Net losses on financial instruments
0.50	0.59	0.27	0.23	Transaction and integration related costs1
0.05	0.07	0.04	0.04	Litigation and settlement expenses1
0.51	—	0.25	—	Business dispositions and related items 2
—	—	0.02	—	Business optimization charges 1
(1.03)	—	(1.03)	—	Gain on sale of business
(0.57)	(1.13)	(0.16)	(0.39)	Tax impact of non-GAAP adjustments
1.40	3.49	0.45	1.12	Net adjustment items
(1.5)%	$21.14	$20.82	(14.2)%	$10.30	$8.84	Adjusted shareholders’ earnings per diluted share
Six Months Ended Jun 30	Three Months Ended Jun 30
Change	2024	2025	Change	2024	2025	(In millions)
(14.1)%	$5,925	$5,089	(23.2)%	$2,986	$2,292	Income before income tax expense
(973)	(1,076)	(508)	(486)	Net investment income
(240)	—	(240)	—	Gain on sale of business
246	595	85	131	Net losses on financial instruments
545	685	280	341	Interest expense
278	302	162	147	Amortization of other intangible assets
(3.2)%	$5,781	$5,595	(12.3)%	$2,765	$2,425	Reportable segments operating gain
1. 	Adjustment item resides in the Corporate & Other reportable segment.
2. 	Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
3. 	Totals may not foot due to rounding.

-- 12 of 15 --

13	13
Elevance Health GAAP Reconciliation — Operating Gain, Operating
Expense Ratio, and 2025 Outlook
Six Months Ended Jun 30	Three Months Ended Jun 30
Change	2024	2025	Change	2024	2025	(In millions)
3.5%	$9,952	$10,297	(1.4)%	$5,066	$4,997	Operating expense
Add / (Subtract):
(116)	(133)	(64)	(53)	Transaction and integration related costs1
(11)	(15)	(9)	(10)	Litigation and settlement expenses1
(119)	—	(59)	—	Business dispositions and related items 2
—	—	(4)	—	Business optimization charges 1
(246)	(148)	(136)	(63)	Net adjustment items
4.6%	$9,706	$10,149	0.1%	$4,930	$4,934	Adjusted operating expense
14.8%	$85,496	$98,186	14.3%	$43,223	$49,421	Operating revenue
(110) bp	116%	10.5%	(160) bp	11.7%	10.1%	Operating expense ratio
(110) Bp	11.4%	10.3%	(140) bp	11.4%	10.0%	Adjusted operating expense ratio
Six Months Ended Jun 30	Three Months Ended Jun 30
Change	2024	2025	Change	2024	2025	(In millions)
(3.2)%	$5,781	$5,595	(12.3)%	$2,765	$2,425	Reportable segments operating gain
Add / (Subtract):
116	133	64	53	Transaction and integration related costs1
11	15	9	10	Litigation and settlement expenses1
119	—	59	—	Business dispositions and related items 2
—	—	4	—	Business optimization charges 1
246	148	136	63	Net adjustment Items
(4.7)%	$6,027	$5,743	(14.2)%	$2,901	$2,488	Reportable segments adjusted operating gain
Full Year 2025
Outlook
Approximately $24.10	Shareholders’ earnings per diluted share
Add / (Subtract):
$3.28	Net losses on financial instruments3
$2.98	Amortization of other intangible assets3
$1.35	Transaction and integration related costs1, 3
$0.10	Litigation and settlement expenses1, 3
Approximately ($1.81)	Tax impact of non-GAAP adjustments3
$5.90	Net adjustment items
Approximately $30.00	Adjusted shareholders’ earnings per diluted share
1. 	Adjustment item resides in the Corporate & Other reportable segment.
2. 	Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
3. 	Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.

-- 13 of 15 --

14	14
Elevance Health
Reportable Segment Highlight Details
Six Months Ended Jun 30	Three Months Ended Jun 30
Change	2024	2025	Change	2024	2025	(In millions, Unaudited)
Operating Revenue
11.6%	$74,417	$83,013	11.9%	$37,159	$41,582	Health Benefits
23.3%	16,841	20,759	21.3%	8,774	10,643	CarelonRx
63.4%	8,554	13,977	63.7%	4,545	7,441	Carelon Services
59.4%	249	397	90.2%	122	232	Corporate & Other
NM 5	(14,565)	(19,960)	NM 5	(7,377)	(10,477)	Eliminations
14.8%	$85,496	$98,186	14.3%	$43,223	$49,421	Total Operating Revenue1
Operating Gain (Loss)
(14.8)%	$4,432	$3,777	(27.3)%	$2,145	$1,560	Health Benefits 2
11.6%	1,020	1,138	7.8%	497	536	CarelonRx
78.9%	498	891	92.3%	208	400	Carelon Services2
NM 5	(169)	(211)	NM 5	(85)	(71)	Corporate & Other 2,3
(3.2)%	$5,781	$5,595	(12.3)%	$2,765	$2,425	Total Operating Gain1,4
Operating Margin
(150) bp	6.0%	4.5%	(200) bp	5.8%	3.8%	Health Benefits
(60) bp	6.1%	5.5%	(70) Bp	5.7%	5.0%	CarelonRx
60 bp	5.8%	6.4%	80 bp	4.6%	5.4%	Carelon Services
(110) bp	6.8%	5.7%	(150) Bp	6.4%	4.9%	Total Operating Margin1
1. 	See “Basis of Presentation” on slide 14 herein.
2. 	Operating Gain for the three and six months ended June 30, 2024, included $59 and $119 million, respectively, of 2024 business dispositions and related items; including $44 and $88 million, respectively, for the Carelon Services segment; and $15 and $31
million, respectively, for the Health Benefits segment. Operating Gain for the three and six months ended June 30, 2024, included $64 and $116 million, respectively, of transaction and integration related costs, $9 and $11 million, respectively, of litigation
and settlement expenses, and $4 and $0 million, respectively, of business optimization charges, all of which reside in the Corporate & Other reportable segment.
3. 	Operating Gain for the three and six months ended June 30, 2025, included $53 and $133 million, respectively, of transaction and integration related costs and $10 and $15 million, respectively, of litigation and settlement expenses, which reside in the
Corporate & Other reportable segment.
4. 	Operating Gain for the three and six months ended June 30, 2025, and June 30, 2024, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on slides 13 and 14 herein.
5. 	"NM" = calculation not meaningful.
Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program
businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not
allocated to our other reportable segments).

-- 14 of 15 --



-- 15 of 15 --